ANGPT2 (angiopoietin-2) is a context-dependent modulator of endothelial cell signaling that binds to the TEK/TIE2 receptor, competing with ANGPT1 for the same binding site 1. ANGPT2 can independently induce TEK/TIE2 tyrosine phosphorylation and modulate ANGPT1 signaling 1. Its biological effects are context-dependent: in the absence of angiogenic inducers like VEGF, ANGPT2-mediated loosening of cell-matrix contacts induces endothelial cell apoptosis and vascular regression; conversely, in concert with VEGF, it facilitates endothelial cell migration and proliferation, serving as a permissive angiogenic signal 1. ANGPT2 also regulates lymphangiogenesis 1. Dysregulated ANGPT2 expression contributes to multiple vascular diseases. In age-related macular degeneration and diabetic macular edema, dual inhibition of ANGPT2 and VEGF-A via the bispecific antibody faricimab demonstrates sustained efficacy with extended dosing intervals, supporting the role of ANGPT2 inhibition in promoting vascular stability 23. Similarly, in retinal vein occlusion, faricimab shows superior efficacy in achieving angiographic macular leakage resolution compared to VEGF-alone inhibition 4. In venous malformations driven by PIK3CA mutations, ANGPT2 suppression and TIE2 inhibition effectively suppress disease progression, identifying a PI3K-FOXO1-ANGPT2-TIE2 circuit as disease-critical 5.